Lung & tracheal cancer, malignant (ICD10 C33-C34): combined sexes
One-year relative survival by diagnosis year and age at diagnosis
|
One-year relative survival (with 95% confidence interval) by diagnosis year |
||||||||||||
|
Age at diagnosis |
1994-97 |
1998-2002 |
2003-2007 |
2007-2009 |
||||||||
|
cohort |
cohort |
cohort |
*hybrid |
|||||||||
|
all 15-99 |
23.6% |
24.9% |
29.9% |
30.4% |
||||||||
|
(unstandardized) |
(22.4-24.7%) |
(23.9-25.9%) |
(28.8-30.9%) |
(29.2-31.6%) |
||||||||
|
all 15-99 |
25.0% |
26.7% |
32.0% |
32.5% |
||||||||
|
(age-standardized)# |
(22.1-27.8%) |
(24.1-29.1%) |
(29.5-34.4%) |
(29.3-35.5%) |
||||||||
|
15-44 |
45.3% |
45.7% |
56.3% |
53.7% |
||||||||
|
(35.5-54.5%) |
(37.8-53.2%) |
(48.4-63.3%) |
(43.8-62.5%) |
|||||||||
|
45-54 |
30.8% |
34.4% |
42.6% |
40.9% |
||||||||
|
(26.4-35.2%) |
(30.5-38.2%) |
(38.7-46.3%) |
(36.2-45.6%) |
|||||||||
|
55-64 |
25.3% |
30.7% |
37.5% |
39.3% |
||||||||
|
(22.7-27.9%) |
(28.3-33.1%) |
(35.2-39.6%) |
(36.4-42.1%) |
|||||||||
|
65-74 |
24.4% |
24.7% |
29.6% |
31.1% |
||||||||
|
(22.5-26.1%) |
(23.0-26.3%) |
(27.8-31.3%) |
(28.8-33.4%) |
|||||||||
|
75-99 |
18.2% |
17.7% |
19.9% |
19.8% |
||||||||
|
(16.3-20.0%) |
(16.1-19.2%) |
(18.4-21.5%) |
(17.9-21.7%) |
|||||||||
Five-year relative survival by diagnosis year and age at diagnosis
|
Five-year relative survival (with 95% confidence interval) by diagnosis year |
EUROCARE-4 |
EUROCARE-4 |
||||||||||
|
Age at diagnosis |
1994-97 |
1998-2002 |
2003-2007 |
2007-2009 |
##2000-2002 |
##2000-2002 |
||||||
|
cohort |
cohort |
cohort |
*hybrid |
Ireland |
Europe average |
|||||||
|
all 15-99 |
8.6% |
9.4% |
11.7% |
12.2% |
||||||||
|
(unstandardized) |
(7.8-9.5%) |
(8.7-10.1%) |
(10.7-12.7%) |
(11.1-13.2%) |
||||||||
|
all 15-99 |
9.3% |
10.2% |
12.7% |
13.3% |
10.9% |
10.9% |
||||||
|
(age-standardized)# |
(7.3-11.6%) |
(8.5-12.2%) |
(10.5-15.2%) |
(10.7-16.0%) |
(9.8-12.2%) |
(10.5-11.4%) |
||||||
|
15-44 |
28.1% |
27.0% |
32.5% |
35.0% |
||||||||
|
(19.8-37.0%) |
(20.4-34.1%) |
(24.5-40.7%) |
(25.6-44.5%) |
|||||||||
|
45-54 |
10.7% |
11.9% |
17.8% |
17.1% |
||||||||
|
(7.9-13.8%) |
(9.4-14.6%) |
(14.5-21.4%) |
(13.4-21.0%) |
|||||||||
|
55-64 |
8.5% |
12.2% |
12.9% |
13.9% |
||||||||
|
(6.9-10.3%) |
(10.5-14.0%) |
(10.9-14.9%) |
(11.7-16.1%) |
|||||||||
|
65-74 |
9.0% |
8.1% |
10.9% |
11.5% |
||||||||
|
(7.8-10.4%) |
(7.0-9.3%) |
(9.4-12.5%) |
(9.8-13.3%) |
|||||||||
|
75-99 |
5.2% |
6.1% |
7.6% |
7.9% |
||||||||
|
(4.0-6.6%) |
(5.0-7.4%) |
(6.1-9.4%) |
(6.3-9.7%) |
|||||||||
|
Footnotes: |
|
|
*Hybrid estimate for 2007-2009 is the most up-to-date survival estimate and is based on follow-up of all cases alive at any point during this period, |
|
|
supplemented by follow-up 2005-2009 for cases diagnosed in 2005-2006 (to provide more reliable estimation of the first two years of survival). |
|
|
In practice, the hybrid estimate for 2007-2009 is similar to the most recent (incomplete) cohort, i.e. cases diagnosed 2003-2007, reflecting substantial overlap of data. |
|
|
# Age-standardized figures use the standard patient population proposed for this cancer by: |
|
|
Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316. |
|
|
(Population weights = age 15-44 x7000, 45-54 x12000, 55-64 x23000, 65-74 x29000, 75-99 x29000) |
|
|
## For comparison, the age-standardized average survival (2000-2002) is quoted for countries (including Ireland) that participated in the EUROCARE-4 study: |
|
|
Verdecchia A., Francisci S., Brenner H., et al. 2007. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8: 784-796. |
|
|
Exclusions (as in EUROCARE): |
|
|
Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient |
|
|
(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour. |
|
|
© National Cancer Registry Ireland 2011 (October 2011) Relative survival statistics for Irish cancer patients |
|